WEBVTT

00:00:02.200 --> 00:00:07.951
CJC-1295 began with a biotechnology challenge: how
do you make a brief hormone

00:00:07.951 --> 00:00:09.769
signal last for days?

00:00:09.950 --> 00:00:15.435
At ConjuChem in Montreal, Canada, Lucie Jetté,
Roger Léger and colleagues engineered a

00:00:15.435 --> 00:00:18.688
longer-acting version of growth hormone-releasing
hormone.

00:00:19.097 --> 00:00:24.025
Their 2005 paper described the molecule's
development, giving it more than twenty years

00:00:24.025 --> 00:00:25.570
of published research history.

00:00:25.700 --> 00:00:29.831
The key technology is called the drug affinity
complex, or DAC.

00:00:29.994 --> 00:00:35.172
It allows the peptide to attach to albumin, a
protein already circulating in the bloodstream.

00:00:35.422 --> 00:00:40.039
This molecular hitchhiking helps the signal remain
in circulation much longer.

00:00:40.265 --> 00:00:45.944
CJC-1295 stimulates receptors on the pituitary
gland, encouraging the

00:00:45.944 --> 00:00:48.398
body to release growth hormone.

00:00:48.644 --> 00:00:53.670
Growth hormone then supports production of insulin-
like growth factor one, an important

00:00:53.670 --> 00:00:56.760
signal involved in tissue growth and metabolism.

00:00:56.932 --> 00:01:02.365
In two placebo-controlled trials published in 2006,
Sam Teichman and colleagues

00:01:02.601 --> 00:01:04.237
studied healthy adults.

00:01:04.465 --> 00:01:09.082
After a single injection, average growth hormone
levels rose for at least six days,

00:01:09.262 --> 00:01:14.424
while insulin-like growth factor one remained
elevated for nine to eleven days.

00:01:14.595 --> 00:01:17.549
Those findings demonstrated sustained hormone
stimulation.

00:01:17.764 --> 00:01:22.523
They did not establish improvements in strength,
recovery, fat loss or longevity.

00:01:22.682 --> 00:01:27.998
Another important distinction: products called
CJC-1295 without

00:01:27.998 --> 00:01:30.970
DAC are not the same long-acting molecule.

00:01:31.041 --> 00:01:35.186
Findings from the albumin-binding version cannot
simply be transferred to them.

00:01:35.372 --> 00:01:41.727
CJC-1295 remains an investigational peptide,
without an FDA-approved use.

00:01:41.934 --> 00:01:47.438
Reported safety concerns include increased heart
rate and reactions involving blood-vessel widening.

00:01:47.622 --> 00:01:52.211
Its research story is one of molecular engineering:
extending the lifetime of a

00:01:52.211 --> 00:01:56.683
biological message, and studying what that longer
signal can achieve.

00:01:56.864 --> 00:01:58.691
World Peptide Foundation.

00:01:58.790 --> 00:01:59.908
Peptides in 2.

00:02:00.058 --> 00:02:01.630
Every experience matters.